Er­ic Os­tertag reach­ing the end of the line as Po­sei­da chief, will be­come ex­ec­u­tive chair­man; Alec­tor ex­ec named CEO of Pfiz­er-backed LNP biotech

→ The Po­sei­da ad­ven­ture takes an­oth­er turn as CEO Er­ic Os­tertag dives in­to the role of ex­ec­u­tive chair­man and CBO Mark Ger­gen steers the ship start­ing Feb. 1. Os­tertag talked through Po­sei­da’s ear­ly proof-of-con­cept da­ta with its PS­MA-tar­get­ing CAR-T for prostate can­cer pa­tients in Au­gust 2021, and the San Diego biotech fol­lowed that up by ink­ing a $3.6 bil­lion-plus gene ther­a­py deal with Take­da in Oc­to­ber.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN